DE1058516B - Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline - Google Patents

Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline

Info

Publication number
DE1058516B
DE1058516B DEK32729A DEK0032729A DE1058516B DE 1058516 B DE1058516 B DE 1058516B DE K32729 A DEK32729 A DE K32729A DE K0032729 A DEK0032729 A DE K0032729A DE 1058516 B DE1058516 B DE 1058516B
Authority
DE
Germany
Prior art keywords
theophylline
dimethylamine
preparation
dimethylaminoaethyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEK32729A
Other languages
German (de)
Inventor
Dr Oskar Ehrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Priority to DEK32729A priority Critical patent/DE1058516B/en
Publication of DE1058516B publication Critical patent/DE1058516B/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Description

Verfahren zur Herstellung von 8-(a-Dimethylaininoäthyl)-theophylliß Gegenstand der Erfindung ist die Herstellung von 8-(a-Dimethylaminoäthyl)-theophyllin. Diese neue Verbindung wird- dadurch hergestellt, daß man 8-(a-Halogenäthyl)-theophyllin mit Dimethylamin umsetzt oder Dimethylamin auf 1,3-Dimethyl-2,5=d'iöxo-4-amino-5-(achlorpröpionylamino)-tetrahydropyrimidin einwirken läBt und die erhaltene tertiäre Base durch Einwirken vors alkalischen Mitteln cyclisiert.Process for the preparation of 8- (a-Dimethylaininoäthyl) -theophylliß The invention relates to the production of 8- (a-dimethylaminoethyl) -theophylline. This new compound is produced by using 8- (a-haloethyl) -theophylline Reacts with dimethylamine or dimethylamine to 1,3-dimethyl-2,5 = d'iöxo-4-amino-5- (achlorpropionylamino) -tetrahydropyrimidine Can act and the tertiary base obtained by acting before alkaline Means cyclized.

Die Base bildet mit anorganischen und organischen Säuren Salze, die in Wasser leicht löslich sind. Die wäßrigen Lösungen sind auch in der Hitze beständig.The base forms salts with inorganic and organic acids, the are easily soluble in water. The aqueous solutions are also resistant to heat.

Das neue Theophyllinderivat unterscheidet sich grundsätzlich von Theophyllin selbst und den bekannten Theophyllinpräparaten, wie Theophyllin-äthylendiamin, Theophyllin - diäthanolamin, 7 - (Dioxypropyl) - theophyllin, 7-(ß-Oxyalkyl)-theophyllin, 7-(ß-Chloräthyl)-theophyllin, 8-(n-Dibutylaminoalkyl)-theophylline, durch seine lang anhaltende blutdrucksenkende Wirkung, die mit Dosen zu erreichen ist, die weit unterhalb der für andere Theophyllinderivate geltenden Dosierungsbereiche liegen. So wurde als Grenzschwellendosis bei intravenöser Injektion am Hund und an der Katze 0,2 mg/kg ermittelt. In der etwa 10fach höheren Dosis ist die Verbindung selbst peroral wirksam und übertrifft damit die meisten der bekannten Theophyllinabkömmlinge bei intravenöser Anwendung (vgl. nachstehende Tabelle). 8-(a-Dimethylaminoäthyl)- 8-(a-Diäthylamino-äthyl)- 8-(Dimethylaminomethyl)- theophyllin theophyllin theophyllin Blutdrucksenkung Versuchstier: Katze 0,2 bis 0,5 mg/kg 3 bis 5 mg/kg 0,15 bis 0,2 mg/kg Applikation: intravenös lokal stark reizend, daher für subcutane und intra- venöse Injektion wenig ge- eignet Diurese Versuchstier: Ratte 6 mg/kg beginnende Wir- bis 50 mg/kg keine Wirkung bis 50 mg/kg keine Wirkung kung, 12 bis 15 mg/kg Applikation: per os starke Wirkung Toxizität D L5, Versuchstier: Maus 162 mg/kg 140 mg/kg 188 mg/kg Applikation: intravenös Die Größe der Blutdrucksenkung steht in absoluter Relation zur Höhe der verabreichten Dosis. Im Vergleich mit der akut toxisch wirkenden Dosis an der Maus zeigt sich, daß die DL., etwa 400mal so hoch ist als die doppelte Grenzschwellendosis im Blutdrucktest an der Katze.The new theophylline derivative differs fundamentally from theophylline itself and the well-known theophylline preparations such as theophylline-ethylenediamine, theophylline-diethanolamine, 7- (dioxypropyl) -theophylline, 7- (ß-oxyalkyl) -theophylline, 7- (ß-chloroethyl) -theophylline , 8- (n-Dibutylaminoalkyl) -theophylline, due to its long-lasting antihypertensive effect, which can be achieved with doses that are far below the dosage ranges applicable to other theophylline derivatives. The threshold dose determined for intravenous injection in dogs and cats was 0.2 mg / kg. In the approximately 10-fold higher dose, the compound itself is effective orally and thus surpasses most of the known theophylline derivatives when administered intravenously (see table below). 8- (a-dimethylaminoethyl) - 8- (a-diethylaminoethyl) - 8- (dimethylaminomethyl) - theophylline theophylline theophylline Lowering blood pressure Test animal: cat 0.2 to 0.5 mg / kg 3 to 5 mg / kg 0.15 to 0.2 mg / kg Application: intravenous locally strongly irritating, therefore for subcutaneous and intra- venous injection little suitable Diuresis Test animal: rat 6 mg / kg incipient we- up to 50 mg / kg no effect up to 50 mg / kg no effect kung, 12 to 15 mg / kg Application: strong effect per os Toxicity D L5, Test animal: mouse 162 mg / kg 140 mg / kg 188 mg / kg Application: intravenous The size of the decrease in blood pressure is in absolute relation to the level of the dose administered. In comparison with the acutely toxic dose in the mouse, it can be seen that the DL., Is about 400 times as high as twice the threshold dose in the blood pressure test on the cat.

Schon in kleinen Dosen per os kann eine statistisch gesicherte Steigerung der Diurese bei gleichzeitig erhöhter Abgabe von Chlorionen nachgewiesen werden. Dabei ist der diuretische Effekt in seiner Größe ebenfalls von der Dosis abhängig; die untere Diurese-Grenzschwellendosis beträgt an der Ratte 6 mg/kg per os. Die neue Verbindung ist sowohl allgemein als auch örtlich gut verträglich und besitzt den Vorteil, gleichzeitig in geringem Maß zentralerregend zu wirken. Sie erscheint für die Behandlung spastisch bedingter Kreislaufveränderungen und bestimmter Formen von krankhaft erhöhtem Blutdruck besonders geeignet.Even in small doses per os there can be a statistically reliable increase the diuresis with simultaneously increased release of chlorine ions can be detected. The size of the diuretic effect is also dependent on the dose; the lower limit threshold dose for diuresis is 6 mg / kg per os in rats. the new compound is well tolerated and possessed both generally and locally the advantage of having a small central excitement at the same time. She appears for the treatment of spastic circulatory changes and certain forms particularly suitable for pathologically increased blood pressure.

Beispiel 1 In eine Lösung von 17g Dimethylamin in 500 ccm wasserfreiem Benzol werden im Rührautoklav 30g 8-(a-Chloräthyl)-theophyllin eingetragen und unter Rühm ren 4 Stunden auf 80 bis 90° C erhitzt. Nach dem Abkühlen wird das ausgeschiedene Dimethylamin-hydrocWorid abgetrennt und aus der klaren Lösung bei °0 C das Verfahrensprodukt auskristallisiert. Das Kristallisat wird mit- Aceton gewaschen, aus Aceton-Alkohol unter Zusatz von Tierkohle umkristallisiert. Man erhält 26,5 g der gewünschten Base vom F-189° C, entsprechend 86 °/o der Theorie. Das HydrochIond der Base schmilzt bei 220 bis 222° C. - -Beispiel 2 -In--eine L-ösung--von 50g- 1,3-Dimethyl-2;6-dioxö= 4-amino-5-(a-chlorpropionylamino)-tetrahydropyrimuidin, erhalten durch Umsetzung von 1,3-Dimethyl-2,6-dioxo-4-amino-5 - (a-oxypropionylamino) -tetrahydropyrimidin mit Thionylchlorid, werden 18g Dimethylamin in 200 ccm Alkohol eingetragen und die--Reaktionsmischung unter Rühren so lange unter RückfluB gekocht, bis klare Lösung eingetreten ist. Man läBt im Kühlschrank auskristallisieren und erhält nach dem Umkristallisieren aus Alkohol 1,3-Dimethyl-2,6-dioxo-4-amino-5-(a-dimethylaminopropionylamino)-tetrahydropyrimidin; F.203. EXAMPLE 1 30 g of 8- (a-chloroethyl) theophylline are introduced into a solution of 17 g of dimethylamine in 500 cc of anhydrous benzene in a stirred autoclave and heated to 80 to 90 ° C. for 4 hours with stirring. After cooling, the precipitated dimethylamine hydrochloride is separated off and the process product is crystallized from the clear solution at ° C. The crystals are washed with acetone and recrystallized from acetone-alcohol with the addition of animal charcoal. 26.5 g of the desired base are obtained at a temperature of 189 ° C., corresponding to 86% of theory. The hydrochloride of the base melts at 220 to 222 ° C. - Example 2 -In - a L solution - of 50g- 1,3-dimethyl-2; 6-dioxo = 4-amino-5- (a- chlorpropionylamino) tetrahydropyrimuidine, obtained by reacting 1,3-dimethyl-2,6-dioxo-4-amino-5 - (a-oxypropionylamino) tetrahydropyrimidine with thionyl chloride, 18 g of dimethylamine are added to 200 cc of alcohol and the reaction mixture refluxed with stirring until a clear solution has appeared. It is allowed to crystallize in the refrigerator and, after recrystallization from alcohol, 1,3-dimethyl-2,6-dioxo-4-amino-5- (a-dimethylaminopropionylamino) tetrahydropyrimidine is obtained; F.203.

Durch Erhitzung der erhaltenen Base mit 10%iger Natronlauge erhält man die Natriumverbindung von 8-(a-Dimethylariünoäthyl)-theophyllin, aus der durch Versetzen mit Mineralsäure und Ausfällen mit Natriumcarbonatlösung die gewünschte Base erhalten wird. Ausbeute: 72°/o der Theorie.Obtained by heating the base obtained with 10% sodium hydroxide solution one the sodium compound of 8- (a-Dimethylariünoäthyl) -theophylline, from which by Adding mineral acid and precipitating with sodium carbonate solution the desired Base is obtained. Yield: 72% of theory.

Claims (1)

PATENTANSPRUCH: Verfahren zur Herstellung von 8-(a-Dimethylaminoäthyl)-theophyllin, dadurch gekennzeichnet, daB man 8-(a-Halogenäthyl)-theophyllin mit Dimethylamin umsetzt oder 1,3-Dimethyl-2,6=dioxo-4-amino-5-(achlorpropionylamino)-tetrahydropyrimidin mit Dimethylamin kondensiert und die erhaltene tertiäre Base cyclisiert. In Betracht gezogene -Druckschriften: Deutsche Patentschrift Nr: 209 728; deutsche Patentanmeldung K 18 901 IVb/12p (bekanntgemacht am 9. 12. 1954). .PATENT CLAIM: Process for the production of 8- (a-dimethylaminoethyl) -theophylline, characterized in that 8- (a-haloethyl) -theophylline is mixed with dimethylamine converts or 1,3-dimethyl-2,6 = dioxo-4-amino-5- (achlorpropionylamino) tetrahydropyrimidine condensed with dimethylamine and cyclized the tertiary base obtained. Into consideration Drawn printed publications: German Patent No. 209 728; German patent application K 18 901 IVb / 12p (published on December 9, 1954). .
DEK32729A 1957-08-17 1957-08-17 Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline Pending DE1058516B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEK32729A DE1058516B (en) 1957-08-17 1957-08-17 Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEK32729A DE1058516B (en) 1957-08-17 1957-08-17 Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline

Publications (1)

Publication Number Publication Date
DE1058516B true DE1058516B (en) 1959-06-04

Family

ID=7219528

Family Applications (1)

Application Number Title Priority Date Filing Date
DEK32729A Pending DE1058516B (en) 1957-08-17 1957-08-17 Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline

Country Status (1)

Country Link
DE (1) DE1058516B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209728C (en) *

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE209728C (en) *

Similar Documents

Publication Publication Date Title
DE1058516B (en) Process for the preparation of 8- (ª ‡ -Dimethylaminoaethyl) -theophylline
DE1470012A1 (en) 7-Theophyllinyl-n-propane-omega-sulfonic acid and a process for its preparation
DE872947C (en) Process for the production of basic ethers, thioether and their salts
DE1543295C3 (en) N-substituted anthranilic acids, their salts, processes for the preparation of these compounds and medicaments containing these compounds
DE1253717C2 (en) PROCESS FOR THE PRODUCTION OF O, S-DIALCOXYCARBONYL VITAMIN B DEEP 1 DERIVATIVES
DE958562C (en) Process for the production of new pyridazines
DE1670378C (en) Process for the preparation of the salt from 4-n-butyl-3,5-dioxo-1,2-diphenylpyrazolidine and the beta-diethylamino-ethylamide of p-chlorophenoxyacetic acid
DE1445142C3 (en) 2- (Benzolsurfonamido) -5-methoxyethoxypyrimidine derivatives
AT234700B (en) Process for the preparation of the new 2-methyl-3- (2'-methyl-3'-chlorophenyl) -quinazolons- (4)
AT218017B (en) Process for the preparation of ketones of 4-hydroxy-coumarin
AT238377B (en) Process for the preparation of the new O-benzoylthiamine disulfide
DE1445028B1 (en) Process for the preparation of 2-benzenesulfonamidopyrimidines
AT92388B (en) Process for the preparation of aralkyl esters of benzylamine carboxylic acids.
DE1961927C (en) 1 ^ -DiphenyM-n-butyl-S.S-dioxoparazolidine sodium monoglycerate, a process for its preparation and pharmaceuticals containing this compound
AT155904B (en) Process for the preparation of 5-ethyl- or 5-allyl-5-isobutyl-2-thiobarbituric acids.
DE668491C (en) Process for the preparation of salicylacylglycol esters
DE513205C (en) Process for the preparation of derivatives of the aminoarylantimony compounds
AT213395B (en) Process for the preparation of the new β-hydroxybutyric acid cyclohexylamide
DE1001272B (en) Process for the preparation of 8- (n-dibutylamino-alkyl) -theophylline compounds
DE1123332B (en) Process for the preparation of 2-methyl-3- (2'-methyl-3'-chlorophenyl) -quinazolon- (4)
CH262798A (en) Process for the preparation of a new pyrimidyl mercaptocarboxylic acid.
DE1123332A (en) Process for the preparation of 2 methyl-3 (2'-methyI-3 chlorophenyl) chmazolone (4)
DE1215716B (en) Process for the preparation of thiobarbituric acid derivatives
CH285024A (en) Process for the preparation of a pyrimidylaminoquinoline derivative.
DE1172267B (en) Process for the preparation of the bis-guaiacol-sulfonic acid salt of morphine-ª ‰ -morpholyl-ethyl-ether